Guru Fundamental Report for JNJ

Validea's analysis rates Johnson & Johnson (JNJ) at 77% using its P/B Growth Investor model, a strategy based on Partha Mohanram's academic work identifying outperforming growth stocks with low book-to-market ratios. While JNJ, a large-cap biotech/drug stock, passed most fundamental criteria for sustained growth, it notably failed tests for Advertising to Assets and Research and Development to Assets, indicating potential areas for investor scrutiny despite its overall strong rating by this specific model.

Analysis

Johnson & Johnson (JNJ) receives a moderately positive rating of 77% from Validea's P/B Growth Investor model, a framework designed to identify high-potential growth stocks with low book-to-market ratios. This score, while favorable, sits just below the 80% threshold indicating formal interest from the strategy. The analysis reveals a dichotomous fundamental picture: JNJ passes multiple tests for financial health and stability, including Return on Assets, Cash Flow from Operations to Assets, and low variance in both sales and asset returns. However, the company fails on two key growth-oriented metrics: Advertising to Assets and, more critically for a pharmaceutical firm, Research and Development to Assets. This suggests that while JNJ exhibits strong current operational performance and stability, its investment in future growth drivers like R&D and brand promotion may not meet the model's criteria for a top-tier growth stock.

Key Decisions for Investors

• Investors should weigh JNJ's demonstrated operational stability, evidenced by strong cash flow and return on assets, against the potential red flags raised by its lower-than-expected R&D and advertising expenditures relative to its asset base.
• For a company in the Biotechnology & Drugs industry, the failure on the R&D to Assets metric warrants further due diligence to assess whether this reflects capital efficiency or a potential weakness in its long-term innovation pipeline.
• Given the 77% score is positive but not a strong conviction signal from this specific growth model, it may be prudent for investors to hold existing positions and monitor future reports for changes in R&D investment and its impact on growth before initiating or adding to a position.